CDKN2A and glioblastoma: Eighty percent (12/15) of BRAF mutated glioblastomas concurrently harbored CDKN2A homozygous deletion, compared with 26.4% (19/72) of BRAF wild-type glioblastomas (p = 0.0002) (Figure 2a).